Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | HBB | P68871 | 2/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nogalamycin SCHEMBL4472 | 1.00 | HSD17B10 (0.72) | HSD17B10ALDH1A1CYP1A2HPGDALOX15 | |
| Nogalamycin SCHEMBL29356331 | 1.00 | HSD17B10 (0.72) | HSD17B10ALDH1A1CYP1A2HPGDALOX15 | |
| Nogalamycin SCHEMBL1649692 | 1.00 | HSD17B10 (0.72) | HSD17B10ALDH1A1CYP1A2HPGDALOX15 | |
| Nogalamycinic Acid SCHEMBL30055177 | 0.95 | HSD17B10 (0.65) | HSD17B10ALDH1A1CYP1A2HPGDALOX15 | |
| SCHEMBL18567081 | 0.91 | HSD17B10 (0.72) | HSD17B10ALDH1A1CYP1A2HPGDALOX15 | |
| Disnogamycin SCHEMBL29390994 | 0.88 | HSD17B10 (0.55) | HSD17B10ALDH1A1CYP1A2HPGDALOX15 | |
| Disnogamycin SCHEMBL26459009 | 0.88 | HSD17B10 (0.55) | HSD17B10ALDH1A1CYP1A2HPGDALOX15 | |
| SCHEMBL3345418 | 0.84 | HSD17B10 (1.00) | HSD17B10ALDH1A1CYP1A2HPGDALOX15 | |
| SCHEMBL11468050 | 0.84 | HSD17B10 (1.00) | HSD17B10ALDH1A1CYP1A2HPGDALOX15 | |
| SCHEMBL18593716 | 0.77 | HSD17B10 (0.52) | HSD17B10ALDH1A1CYP1A2HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 32173 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4698185-A1 | METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES | Osasuna Therapeutics SA (CH) | 2026-02-25 | — | — | EP | claimed |
| WO-2000028087-A1 | A LIBRARY OF MODIFIED PRIMERS FOR NUCLEIC ACID SEQUENCING, AND METHOD OF USE THEREOF | SEQUETECH CORPORATION (US) | 2000-05-18 | — | — | WO | claimed |
| EP-1000078-A1 | HYBRID ANTHRACYCLINES FROM GENETICALLY ENGINEERED $i(STREPTOMYCES GALILAEUS) STRAINS | GALILAEUS OY (FI) | 2000-05-17 | — | — | EP | claimed |
| WO-1999058126-B1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | ENDOWMENT RES INHUMAN BIOLOGY (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999058544-A9 | HYBRID ANTHRACYCLINES FROM GENETICALLY ENGINEERED STREPTOMYCES GALILAEUS STRAINS | GALILAEUS OY (FI) | 2000-01-20 | — | — | WO | claimed |
| WO-1999058544-A1 | HYBRID ANTHRACYCLINES FROM GENETICALLY ENGINEERED STREPTOMYCES GALILAEUS STRAINS | GALILAEUS OY (FI) | 1999-11-18 | — | — | WO | claimed |
| WO-1999058126-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| EP-0316440-B1 | System and method for providing localized Mössbauer absorption in an organic medium | MILLS RANDELL L (US) | 1996-01-03 | — | — | EP | claimed |
| WO-1994026253-A1 | LIPOSOME HAVING A MULTICOMPONENT BILAYER WHICH CONTAINS A BIOACTIVE AGENT AS AN INTEGRAL COMPONENT OF THE BILAYER | THE LIPOSOME COMPANY, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| WO-1992005200-A1 | XENOBIOTIC-ANTIBODY CONJUGATES | CHEMEX PHARMACEUTICALS, INC. (US) | 1992-04-02 | — | — | WO | claimed |
| US-4329450-A | Nogalamycin analog containing compounds | THE UPJOHN COMPANY (US) | 1982-05-11 | — | — | US | claimed |